전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-2 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,047 programs
AntibodyLimited DatastaleMarmara UniversityPreclinical

Tociliuzumab (Tociliuzumab)

Takayasu Arteritis · Takayasu Arteritis

#TakayasuArteritis#Antibody#Preclinical#monoclonal-antibody#Marmara
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePreclinical

Actemra® (Tocilizumab, Tocilizumab (Actemra®))

Rheumatoid Arthritis; Inflammation · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Preclinical#monoclonal-antibody#Inflammation+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

Tocilizumab at emerging CRS (Tocilizumab at emerging CRS)

Myeloma; Lymphoma · Myeloma

#Myeloma#Antibody#Phase2#monoclonal-antibody#Lymphoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Tocilizumab before CAR-T cell infusion (Tocilizumab before CAR-T cell infusion)

Myeloma; Lymphoma · Myeloma

#Myeloma#Antibody#Phase2#monoclonal-antibody#Lymphoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 3

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 1Status Recruiting
AntibodyLimited DatastaleDaping Hospital and the Researc…Phase 2

PCSK9 Inhibitor (Tolecizumab, Tolecizumab (PCSK9 Inhibitor))

Colon Adenocarcinoma · Colon Adenocarcinoma

#ColonAdenocarcinoma#Antibody#Phase2#monoclonal-antibody#Daping
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 3

JS001 (Toripalimab, Toripalimab (JS001 ))

Urinary Bladder Neoplasms · Urinary Bladder Neoplasms

#UrinaryBladderNeoplasms#Antibody#Phase3#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab combine with Rituximab (Toripalimab combine with Rituximab)

Diffuse Large B-cell Lymphoma; Rituximab · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#Antibody#Phase2#monoclonal-antibody#Rituximab+1
Trials 1Status Active
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab （12weeks） (Toripalimab （12weeks）)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab （18weeks） (Toripalimab （18weeks）)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab+cetuximab (Toripalimab+cetuximab)

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma · Patients With Locally Recurrent Resectab

#PatientsWithLocallyRecurrentRese#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab, Rituximab (Toripalimab, Rituximab)

Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#monoclonal-antibody#High-gradeB-cellLymphoma+1
Trials 1Status Active
AntibodyLimited DatastaleGlaxoSmithKlinePhase 3

Tositumomab and Iodine I 131 Tositumomab (Tositumomab and Iodine I 131 Tositumomab)

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase3#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
AntibodyLimited DatastaleNorthwestern UniversityPhase 1

Transferrin Receptor-Targeted Liposomal p53 cDNA (Transferrin Receptor-Targeted Liposomal p53 cDNA)

Anatomic Stage IV Breast Cancer AJCC v8; Breast Inflammatory Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#Antibody#Phase1#monoclonal-antibody#BreastInflammatoryCarcinoma+1
Trials 1Status Discontinued
ADCLimited DatastaleDaiichi SankyoPreclinical

T-DXd, ENHERTU® (Trastuzumab Deruxtecan, Trastuzumab Deruxtecan (T-DXd, ENHERTU®))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Preclinical#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan and ivonescimab)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleRochePhase 2

SHR-A1811 (Trastuzumab Rezetecan, Trastuzumab Rezetecan (SHR-A1811))

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveBreastCancer+1
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan + FLO)

Esophagogastric Adenocarcinoma · Esophagogastric Adenocarcinoma

#EsophagogastricAdenocarcinoma#ADC#Phase2#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan-nxki)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastCancer+2
Trials 1Status Recruiting
ADCLimited DatastaleBoryung Pharmaceutical Co., LtdPhase 2

Trastzumab Deruxtecan (Trastzumab Deruxtecan)

Ovarian Cancer; Ovarian Carcinoma, Recurrent · Ovarian Cancer

#OvarianCancer#ADC#Phase2#antibody-drug-conjugate#OvarianCarcinoma+2
Trials 1Status Recruiting

90 / 103 pages

← PreviousNext →